Navigation Links
Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress
Date:7/28/2011

KYOTO, Japan, July 28, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced data from its clinical development program for OBI-1, an intravenous (IV) recombinant porcine factor VIII product (rpFVIII), intended for the treatment of bleeding in people with hemophilia A with inhibitors and in people with acquired hemophilia.  The data were presented in a Scientific Session held in conjunction with the 23rd Congress of the International Society on Thrombosis and Haemostasis (ISTH), which was chaired by Amy Shapiro, M.D., Co-Medical Director at the Indiana Hemophilia and Thrombosis Center (IHTC).

During the Scientific Session, Anne Greist, M.D., Co-Medical Director at IHTC, presented interim results from the first registration study in the OBI-1 Accur8 clinical trial program.  A total of three patients with acquired hemophilia, who had experienced severe bleeds not controlled with by-passing agents, were treated with OBI-1; in all three patients, treatment with OBI-1 stopped the bleeding.  Further data on hemostatic efficacy and safety are being collected as part of the Accur8 clinical trial program, designed to study OBI-1 in acquired hemophilia.  A second study in individuals with congenital hemophilia A who have developed inhibitors against FVIII is set to commence later this year.

Additional reports from the Scientific Session confirmed findings from the Phase 2 study in congenital hemophilia A with inhibitors; that OBI-1 effectively resulted in hemostasis, and controlled all non-life/non-limb threatening bleeding episodes in individuals with congenital hemophilia A and inhibitors, even in the presence of high inhibitor levels. All 25 bleeds in the study were controlled, and twenty out of 25 bleeds (80%) were controlled with two infusions. In over 40 infusions administered, OBI-1 was well tolerated by all participants and no drug-related serious adverse events were observed.

Dr. Gre
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
2. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
3. Siemens MAMMOMAT Inspiration Digital Mammography Commercially Available in U.S.
4. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. National Expressions of Courage Art Contest Unveils Stories of Inspiration
7. Inspiration for My Sisters Keeper Speaks Out
8. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
9. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
10. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
11. Reportlinker Adds India Biopharmaceuticals Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Kensey Nash Corporation (Nasdaq: KNSY ) ... Exemption (IDE) application to the U.S. Food and Drug ... unique biomaterials technology for treating articular cartilage defects of ... Cartilage Repair Device, which consists of a proprietary bi-phasic, ...
... MAP Pharmaceuticals, Inc. announced today that its initial Phase ... the potential treatment of children with asthma did not ... changes from baseline in nighttime and daytime composite symptom ... with placebo. AstraZeneca (NYSE: AZN ) ...
Cached Medicine Technology:Kensey Nash Announces IDE Submission for Cartilage Repair Device 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 3Kensey Nash Announces IDE Submission for Cartilage Repair Device 4AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints 2
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is ... developing, producing and marketing of a series of induction ... their new series of induction brazing equipments . ... induction brazing refers to the joining of ... and heat. The manager says that there are fundamental ...
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... sex hormones, testosterone in men and estrogen in women, ... of cartilage tissue. The study suggests hormone replacement in ... beneficial in treating late stages of human osteoarthritis (OA) ... study appear in the April issue of Arthritis ...
... some viral infections fatal and others much less severe ... part of the variability can be attributed to differences ... Katze, presenting at the Society for General Microbiology,s spring ... be a powerful tool to allow treatments to be ...
... this may be why they are less likely to ... (HealthDay News) -- Preconceived attitudes about breast-feeding may explain ... women to breast-feed their infants, a new study shows. ... 2006 were ever breast-fed, compared with 77 percent of ...
... ARBOR, Mich. While radiation therapy is common after ... even among women for whom it would have clear ... from researchers at the University of Michigan Comprehensive Cancer ... for breast cancer, assessing whether they had lumpectomy or ...
... An important gene that normally protects the body against ... on the specific mutation that damages it, according to ... University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and ... mutations in a gene called PTEN. People who inherit ...
... may affect decision-making and self-control , MONDAY, March 29 ... (CRP) are associated with problems in executive thinking skills, ... study. , CRP is considered an indicator of inflammation. ... scans and were given tests of verbal memory, word ...
Cached Medicine News:Health News:Hormone replacement in joint fluid has potential regenerative effect 2Health News:Personalizing medicine to prevent pandemics 2Health News:Black Women in U.S. Comfortable With Formula Feeding 2Health News:Radiation after mastectomy underused, U-M study finds 2Health News:Study shows that mutations in 1 gene cause many cancers 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: